These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 3444799)

  • 41. Comparison of the efficacy of single and multiple regimens of carbimazole in the treatment of thyrotoxicosis.
    Mafauzy M; Wan Mohamad WB; Zahary MK; Mustafa BE
    Med J Malaysia; 1993 Mar; 48(1):71-5. PubMed ID: 8341175
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves' patients undergoing antithyroid drug (ATD) treatment.
    Giuliani C; Cerrone D; Harii N; Thornton M; Kohn LD; Dagia NM; Bucci I; Carpentieri M; Di Nenno B; Di Blasio A; Vitti P; Monaco F; Napolitano G
    J Clin Endocrinol Metab; 2012 Jul; 97(7):E1080-7. PubMed ID: 22492869
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dissociation of responsiveness to thyrotropin-releasing hormone and thyroid suppressibility following antithyroid drug therapy of hyperthyroidism.
    Martino E; Pinchera A; Capiferri R; Macchia E; Sardano G; Bartalena L; Mazzanti F; Baschieri L
    J Clin Endocrinol Metab; 1976 Sep; 43(3):543-9. PubMed ID: 821960
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Similar clinical performance of a novel chimeric thyroid-stimulating hormone receptor bioassay and an automated thyroid-stimulating hormone receptor binding assay in Graves' disease.
    Kamijo K; Murayama H; Uzu T; Togashi K; Olivo PD; Kahaly GJ
    Thyroid; 2011 Dec; 21(12):1295-9. PubMed ID: 22066477
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Thyrotropin receptor antibodies in hypothyroid Graves' disease.
    Kasagi K; Hidaka A; Nakamura H; Takeuchi R; Misaki T; Iida Y; Konishi J
    J Clin Endocrinol Metab; 1993 Feb; 76(2):504-8. PubMed ID: 8094394
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Absence of gradient of thyrotropin receptor antibody and T cell subset distribution between thyroid and peripheral venous blood in patients with Graves' disease prepared for surgery with carbimazole and potassium iodide.
    Wilson R; McKillop JH; Pearson C; Burnett AK; Gunn I; McNicol AM; Thomson JA
    Clin Exp Immunol; 1988 Aug; 73(2):265-8. PubMed ID: 3263232
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Graves' disease: evolution and prognosis after eight months of treatment with methimazole.
    Gauna AT; Guillén CE; Sartorio GC; Soto RJ
    Medicina (B Aires); 1992; 52(3):207-12. PubMed ID: 1364158
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Thyrotropin receptor antibodies in parotid saliva.
    Tumilasci OR; Arqueros MC; Ostuni MA; el Tamer E; Houssay AB
    J Endocrinol Invest; 1996; 19(7):412-4. PubMed ID: 8884533
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Carbimazole and the autoimmune response in Graves' disease.
    McGregor AM; Petersen MM; McLachlan SM; Rooke P; Smith BR; Hall R
    N Engl J Med; 1980 Aug; 303(6):302-7. PubMed ID: 6247656
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical, biochemical and immunological characteristics of relapsers and non-relapsers of thyrotoxicosis treated with anti-thyroid drugs.
    Chowdhury TA; Dyer PH
    J Intern Med; 1998 Oct; 244(4):293-7. PubMed ID: 9797492
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Neonatal hyperthyroidism caused by TSH receptor antibodies in maternal autoimmune hyperthyroidism].
    Resch B; Mache C; Rosegger H; Häusler M
    Z Geburtshilfe Neonatol; 1995; 199(6):248-52. PubMed ID: 8581851
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Optimum duration of antithyroid drug treatment determined by assay of thyroid stimulating antibody in patients with Graves' disease.
    Edan G; Massart C; Hody B; Poirier JY; Lé Reun M; Hespel JP; Leclech G; Simon M
    BMJ; 1989 Feb; 298(6670):359-61. PubMed ID: 2564286
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
    Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K
    J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differential immunosuppressive action of carbimazole and propylthiouracil.
    Wilson R; McKillop JH; Pearson C; Burnett AK; Thomson JA
    Clin Exp Immunol; 1988 Aug; 73(2):312-5. PubMed ID: 3263234
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Radioimmunoassay of human serum thyrotrophin.
    Hall R; Amos J; Ormston BJ
    Br Med J; 1971 Mar; 1(5749):582-5. PubMed ID: 5548300
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Thyrotropin receptor autoantibodies in Graves' disease.
    Schott M; Scherbaum WA; Morgenthaler NG
    Trends Endocrinol Metab; 2005 Jul; 16(5):243-8. PubMed ID: 15950483
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Neonatal hyperthyroidism in a premature infant born to a mother with Grave's disease].
    Nicaise C; Gire C; Brémond V; Minodier P; Soula F; d'Ercole C; Palix C
    Arch Pediatr; 2000 May; 7(5):505-8. PubMed ID: 10855389
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Differentiation of postpartum Graves' thyrotoxicosis from postpartum destructive thyrotoxicosis using antithyrotropin receptor antibodies and thyroid blood flow.
    Ide A; Amino N; Kang S; Yoshioka W; Kudo T; Nishihara E; Ito M; Nakamura H; Miyauchi A
    Thyroid; 2014 Jun; 24(6):1027-31. PubMed ID: 24400892
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Problems in thyroid function screening using thyroid stimulating hormone. A case of thyrotoxicosis caused by a thyroid stimulating hormone-secreting pituitary tumor].
    Nygaard B
    Ugeskr Laeger; 1995 Oct; 157(41):5728-9. PubMed ID: 7571112
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
    Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.